Compositions and methods for preventing and treating Zika virus infection

Patent metadata

Field	Value
Publication number	US-10611801-B2
Application number	US-201716099254-A
Country	US
Kind code	B2
Filing date	Jun 9, 2017
Priority date	Jun 9, 2016
Publication date	Apr 7, 2020
Grant date	Apr 7, 2020

Abstract

The invention relates to immunogenic compositions and vaccines containing a ZIKV protein or a polynucleotide encoding a Zika virus (ZIKV) protein and uses thereof. The invention also provides methods of treating and/or preventing a ZiKV infection by administering an immunogenic composition or vaccine of the invention to a subject (e.g., a human).

First claim

The invention claimed is:

1. An isolated nucleic acid molecule comprising:
(i) a nucleotide sequence having at least 85% sequence identity to the sequence of any one of SEQ ID NOs: 1, 3, 5, 7, 9, and 11, or a complementary sequence thereof; and/or
(ii) a nucleotide sequence that encodes a polypeptide having at least 85% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 2, 4, 6, 8, 10, and 12.

2. An isolated polypeptide comprising an amino acid sequence having at least 85% sequence identity to the sequence of any one of SEQ ID NOs: 2, 4, 6, 8, 10, or 12.

3. A vector comprising one or more of the nucleic acid molecules of claim 1 .

4. The vector of claim 3 , wherein the vector is a mammalian, bacterial, or viral derived expression vector.

5. The vector of claim 4 , wherein the vector is:
(i) a viral vector derived from a virus selected from the group consisting of a retrovirus, adenovirus, adeno-associated virus, parvovirus, coronavirus, negative strand RNA viruses, orthomyxovirus, rhabdovirus, paramyxovirus, positive strand RNA viruses, picornavirus, alphavirus, double stranded DNA viruses, herpesvirus, Epstein-Barr virus, cytomegalovirus, fowlpox, and canarypox;
(ii) an adenoviral vector derived from an adenovirus selected from the group consisting of Ad2, Ad5, Ad11, Ad12, Ad24, Ad26, Ad34, Ad35, Ad40, Ad48, Ad49, Ad50, Ad52, and Pan9; or
(iii) an adenoviral vector derived from a human, chimpanzee, or rhesus adenovirus.

6. A composition comprising the nucleic acid molecule of claim 1 , a polypeptide encoded by the nucleic acid molecule, or a vector comprising the nucleic acid molecule, wherein, optionally, the composition further comprises:
(i) a pharmaceutically acceptable carrier, excipient, or diluent; and/or
(ii) an adjuvant or an immunostimulatory agent.

7. An immunogenic composition comprising the composition of claim 6 , wherein said immunogenic composition:
(i) is capable of treating or reducing the risk of a ZIKV infection in a subject in need thereof; and/or
(ii) elicits production of neutralizing anti-ZIKV antisera after administration to said subject.

8. An isolated antibody or an antigen-binding fragment thereof that specifically binds to the polypeptide of claim 2 .

9. The antibody of claim 8 , wherein the antibody or antigen-binding fragment thereof is generated by immunizing a mammal with the nucleic acid molecule of claim 1 , a polypeptide encoded by the nucleic acid molecule, a vector comprising the nucleic acid molecule, a composition comprising the nucleic acid molecule, polypeptide, or vector, and/or an immunogenic composition comprising the composition.

10. A method of producing anti-ZIKV antibodies, comprising administering to a subject an amount of at least one of the nucleic acid molecule of claim 1 , a polypeptide encoded by the nucleic acid molecule, a vector comprising the nucleic acid molecule, a composition comprising the nucleic acid molecule, polypeptide or vector, and/or an immunogenic composition comprising the composition, wherein the amount is sufficient to elicit production of neutralizing anti-ZIKV antisera after administration to said subject.

11. An isolated anti-ZIKV antibody produced by the method of claim 10 , wherein the isolated anti-ZIKV antibody binds to an epitope within any one of SEQ ID NOs: 2, 4, 6, 8, 10, or 12.

12. A method of treating or reducing the risk of a ZIKV infection in a subject in need thereof and/or reducing a ZIKV-mediated activity in a subject infected with a ZIKV, wherein said ZIKV-mediated activity is viral titer, viral spread, infection, or cell fusion, the method comprising administering to the subject a therapeutically effective amount of at least one of the nucleic acid molecule of claim 1 , a polypeptide encoded by the nucleic acid molecule, a vector comprising the nucleic acid molecule, a composition comprising the nucleic acid molecule, polypeptide or vector, an immunogenic composition comprising the composition, an antibody specifically binding to the polypeptide, and/or a neutralizing anti-ZIKV antisera produced by administering to a subject the nucleic acid molecule, polypeptide, vector, composition, or immunogenic composition.

13. The method of claim 12 , wherein:
(i) the therapeutically effective amount of the nucleic acid molecule, the polypeptide, the vector, the composition, the immunogenic composition, the antibody, and/or the neutralizing anti-ZIKV antisera is sufficient to produce a log serum anti-Env antibody titer greater than 2 in the subject, as measured by an ELISA assay;
(ii) the therapeutically effective amount is between 15 μg and 300 μg of the nucleic acid molecule, the polypeptide, the vector, the composition, the immunogenic composition, the antibody, and/or the neutralizing anti-ZIKV antisera;
(iii) the ZIKV titer is decreased after administration of the nucleic acid molecule, the polypeptide, the vector, the composition, the immunogenic composition, the antibody, and/or the neutralizing anti-ZIKV antisera; and/or
(iv) the ZIKV is undetectable after administration of the nucleic acid molecule, the polypeptide, the vector, the composition, the immunogenic composition, the antibody, and/or the neutralizing anti-ZIKV antisera.

14. The method of claim 12 , wherein said administering occurs:
(i) prior to exposure to a ZIKV;
(ii) at least 1 hour prior to exposure to said ZIKV;
(iii) post-exposure to the ZIKV; or
(iv) at least 15 minutes post-exposure to said ZIKV.

15. The method of claim 12 , wherein:
(i) the nucleic acid molecule, the polypeptide, the vector, the composition, the immunogenic composition, the antibody, and/or the neutralizing anti-ZIKV antisera is administered to said subject in at least one dose, in at least two doses, as a prime, as a boost, or as a prime-boost; and/or
(ii) the nucleic acid molecule, the polypeptide, the vector, the composition, the immunogenic composition, the antibody, and/or the neutralizing anti-ZIKV antisera is administered to said subject intramuscularly, intravenously, intradermally, percutaneously, intraarterially, intraperitoneally, intralesionally, intracranially, intraarticularly, intraprostatically, intrapleurally, intratracheally, intranasally, intravitreally, intravaginally, intrarectally, topically, intratumorally, peritoneally, subcutaneously, subconjunctivelly, intravesicularlly, mucosally, intrapericardially, intraumbilically, intraocularly, orally, topically, locally, by inhalation, by injection, by infusion, by continuous infusion, by localized perfusion bathing target cells directly, by catheter, by lavage, by gavage, in creams, or in lipid compositions.

16. The method of claim 12 , wherein:
(i) the subject is a mammal;
(ii) the subject is a human;
(iii) the method promotes an immune response in said subject; and/or
(iv) the method promotes a humoral immune response in said subject.

17. A method of manufacturing an immunogenic composition for treating or reducing the risk of a ZIKV infection in a subject in need thereof, said method comprising the steps of:
(a) forming the immunogenic composition by admixing at least one of the nucleic acid molecule of claim 1 , a polypeptide encoded by the nucleic acid molecule, a vector comprising the nucleic acid molecule, a composition comprising the nucleic acid molecule, polypeptide or vector, an antibody specifically binding to the polypeptide, and/or a neutralizing anti-ZIKV antisera produced by administering to a subject the nucleic acid molecule, the polypeptide, the vector, or the composition with a pharmaceutically acceptable carrier, exc

Assignees

• Beth Israel Deaconess Medical Ct Inc

Inventors

• Barouch Dan H
• Abbink Peter
• Larocca Rafael

Classifications

• A61P31/14

  for RNA viruses · CPC title

• C12N2770/24134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• A61K2039/55

  characterised by the host/recipient, e.g. newborn with maternal antibodies · CPC title

• A61K2039/53

  DNA (RNA) vaccination · CPC title